A cross-over trial of debrisoquine and guanethidine in 32 patients showed that both drugs were equally effective in lowering both systolic and diastolic blood pressure. The degree to which they were tolerated by the patients, however, differed greatly. After three months on each drug 18 patients preferred debrisoquine, nine preferred guanethidine, and five showed no particular preference. At current prices the cost of daily treatment to the patient was cheaper with debrisoquine than with guanethidine.
Introduction
Published work shows that both guanethidine and debrisoquine are potent hypotensive agents in the management of moderate to severe cases of hypertension. Though both drugs act on the postganglionic sympathetic nerves, interfering with the release of noradrenaline at their nerve endings, their side effects though similar are not equally severe. Heffernan and Carty (1970) in their initial studies with debrisoquine were impressed with the low incidence of side effects. Though bethanidine, guanethidine, and methyldopa (Prichard et al., 1968) and debrisoquine and methyldopa (Heffernan et al., 1971) have been compared there has been no formal comparative clinical trial between debrisoquine and guanethidine. We therefore made a within-patient comparison of the effectiveness and tolerability of debrisoquine and guanethidine using the principles (with slight modifications) established by Prichard et al. (1968) .
Patients and Methods
Patients were selected to take part in the trial if (a) they had moderate to severe hypertension with a standing diastolic blood pressure of 110 mm Hg or above; (b) they were not ill enough to warrant admission to hospital for either the hypertension or its renal, cardiac, or cerebrovascular complications and so could be safely managed as outpatients; (c) they had had no regular antihypertensive treatment for the past four weeks; and (d) they agreed to attend every two weeks in return for receiving their drugs free of charge.
We explained to the patients that two drugs known to be equally effective in treating hypertension were going to be given to them free of charge for three to four months at a time and that we wanted to know which of the two drugs they preferred and their reasons for such preference.
INITIAL ASSESSMENT
The 85 patients so selected were questioned, using a specially prepared questionnaire form, on Both drugs produced a good control of systolic and diastolic blood pressures, which in fact was our objective. Statistically, however, there was no difference between the mean systolic and diastolic standing blood pressures for these 32 patients on guanethidine and on debrisoquine. The mean (± S.D.) systolic standing blood pressure before the trial was 188-33 i 20-07 mm Hg while the mean after guanethidine was 133-5 ± 18-94 mm Hg and after debrisoquine 134-5 ± 18 83 mm Hg. Similarly, the mean baseline standing diastolic blood pressure was 123 6 ± 1131 mm Hg, and this fell to 88-49 ± 11-38 mm Hg after guanethidine and 92-65 ± 10-98 mm Hg after debrisoquine. At the end of the trial patients were asked which of the two drugs they preferred. Eighteen patients preferred debrisoquine, nine preferred guanethidine, and five said both drugs were equally good. Ignoring those who showed no particular preference the preference of most of the patients for debrisoquine over guanethidine was statistically significant (P <0 05). The reasons for such preference were mainly that debrisoquine caused less postural dizziness, less weakness and shortness of breath and, in the men, fewer instances of delayed ejaculation and diminished libido. Some patients required nasal drops while on guanethidine to relieve nasal stuffiness, particularly at night, but they did not seem to have associated this symptom with the drug until told at the end of the trial.
EFFECT OF ORDER OF DRUG ADMINISTRATION ON PATIENTS' PREFERENCE
The effect of the order of administration of drugs on the patients' stated preference at the end of the trial is shown in table III. Though about the same number of patients were started on each drug in a randomized manner at the beginning of the trial of those who completed the trial 18 received debrisoquine BRITISH MEDICAL JOURNAL 1 MARCH 1975 last and 14 received guanethidine last. Hence there was a pronounced tendency for the patients to prefer the drug last administered-a finding similar to that of Prichard et al. (1968) . Excluding the cost of polythiazide used in the trial the cost to the patient, had he paid for the drugs at retail prices, ranged from U1.50O to t13.20 a month when guanethidine (Ismelin) was used. When debrisoquine (Declinax) was used, however, the cost ranged from N1.50 to W.00 a month. For the group as a whole it cost about -N6.60 a day to use guanethidine in the treatment of hypertension compared with *3.90 a day using debrisoquine, and the average cost per patient per day was bM.20 on guanethidine and N0.12 on debrisoquine. When the cost of polythiazide (Renese), which is one of the cheapest diurectics, is added (NO.05 a tablet) the cost for the whole group of treatment with guanethidine increased still further compared with that of treatment with debrisoquine. We purposely used proprietary drugs in assessing the cost of treatment as prices of unbranded drugs vary. Though unbranded drugs tend to be cheaper, in many developing countries where there is no drug quality control ordinary starch or chalk tablets have been sold under all kinds of generic names.
Discussion
Guanethidine and debrisoquine were equally effective in lowering the blood pressure in cases of moderate to severe hypertension and in only one person were side effects sufficiently severe to warrant discontinuation of the drug during the trial period. The side effects of the two drugs were similar, as would be expected from their known pharmacological action of adrenergic neurone blockade, but they varied in degree. Guanethidine tended to cause more postural dizziness, nasal stuffiness, weakness, and fluid retention than debrisoquine. More patients, therefore, preferred debrisoquine though such a preference must have been partially due to the well-known tendency for patients undergoing this sort of trial to prefer the drug last administered, probably because they become more tolerant of the side effects as the trial proceeds. On the other hand, this factor could not have accounted wholly for the patients' preference for debrisoquine because any really serious side effect of the drug last administered would have been fresh in the mind of the patient at the end of the trial and would have tended to adversely influence his choice of this drug.
There may well be some subtle differences in the action of both drugs in the body which gives debrisoquine a slight edge over guanethidine as far as the patients' subjective assessment is concerned. Obviously more work is needed to test these differences on a larger group of patients and to carry out a more detailed statistical analysis of the results. Both drugs, however, have some serious side effects in men-namely, diminution of libido and delayed or scanty ejaculation, which patients may find very distressing. Though they may feel shy to complain about this to the doctor, especially in the presence of a woman, such side effects are likely to affect adversely the use of these drugs in the long-term management of hypertension in patients who suffer such side effects.
*' 1 00 =£0 66p ($U.S. 1 52) at time of writing.
Debrisoquine's greatest advantage over guanethidine is it's cost. It costs the hypertensive patient about twice as much to be treated with guanethidine as it does to be treated with debrisoquine. For most people in the developing countries, where average incomes are low, and for all people who have to pay for their own drugs this fact is important and should be borne in mind by doctors if life-long treatment of patients' hypertension is to be achieved.
Introduction
The variety and sophistication of pulmonary function tests are ever increasing, but to many doctors, particularly in general practice, "pulmonary function testing" is confined to the use of a recording spirometer, such as a Vitalograph. There are still many clinicians who, despite evidence to the contrary (Levine et al., 1970; Cade and Pain, 1973) , will accept a ratio of forced expiratory volume in one second: forced vital capacity (FEV,: FVC) above 70% as excluding significant airways obstruction and other pulmonary dysfunction in bronchial asthma. We present here further evidence that they are wrong to do so; some patients may have significant-pulmonary hyperinflation and arterial hypoxaemia with hypocapnia.
Patients and Methods
The 35 patients (13 men, 22 women) all had a clinical history of asthma with paroxysmal dyspnoea, wheezing, and blood or sputum eosinophilia or both. Their mean age (± S.D.) was 283 ± 13-8 years. On skin-prick tests 28 reacted imnediately to various allergens, mainly pollen and house-dust mite, and were considered to have extrinsic asthma. Drug treatment was discontinued for at least 12 hours before pulmonary function testing, except in one patient who was taking 5 mg daily of prednisone by mouth and using an aerosol topical steroid (beclomethasone dipropionate) and one wrho was using the aerosol alone.
The following indicators of pulmonary function were measured: dynamic lung volumes: FEVI, FVC, the ratio FEV1:FVC; static l,ung volumes: total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), the ratio RV:TLC; single breath carbon monoxide pulmonary diffusing capacity (DLCO); and arterial blood gases-Pao2, Paco2, and pH. The techniques used were as described previously (Palmer and Kelman, 1973) .
Results
The mean values and percentage of predicted normal values are shown in table I. The mean FEV1:FVC (± S.D.) was 81-0 ± 6-9%, which was within the normal range for this age group (Higgins and Keller, 1973) . Statistically significant differences (P <005) from the normal values predicted by Cotes (1968) were found in FEV1, RV, and RV:TLC. Pao2 and Paco2 also differed significantly (P <0 001) from the normal values found by Diament and Palmer (1969) (Levine et al., 1970; Teculescu and Stanescu, 1970; Mayfield et al., 1971; Cade and Pain, 1973 Pain (1973) found that the mean Pao, was only at the lower limit of
